Crescent Biopharma (CBIO) vs MapLight Therapeutics (MPLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MapLight Therapeutics is the larger company by market cap ($520.2 million vs $501.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | MPLT |
|---|---|---|
| Share price | $13.49 | $9.36 |
| Market cap | $501.11M | $520.19M |
| 1-day change | -0.59% | -3.41% |
| YTD return | +13.74% | -46.71% |
| 1-year return | +19.49% | — |
| 5-year return | -93.19% | — |
| EPS (TTM) | $-7.63 | $-6.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $40.43 |
| 52-week low | $8.72 | $8.92 |
| Distance from 52-week high | -50.78% | -76.85% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +133.51% | +183.55% |
| Average volume | 387.23K | 867.94K |
| Shares outstanding | 37.14M | 52.85M |
| Employees | 69 | 133 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Healthcare · Biotechnology · 69 employees
About MapLight Therapeutics
MPLT stock →MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders.
Healthcare · Biotechnology · 133 employees
CBIO vs MPLT FAQ
Which is bigger, Crescent Biopharma or MapLight Therapeutics?
MapLight Therapeutics (MPLT) is larger, with a market capitalization of $520.19M compared with $501.11M for Crescent Biopharma (CBIO).
Are Crescent Biopharma and MapLight Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.